- call +1-201-465-4211
- email sales@mrinsights.biz
Community-acquired pneumonia (CAP) refers to pneumonia (any of several lung diseases) contracted by a person with little contact with the healthcare system.
Scope of the Report:
The market of CAP treatment and diagnosis in further segmented with respect to major geographies of North America, Europe, Asia-Pacific, and Latin America.
The global Community Acquired Pneumonia (CAP) market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Community Acquired Pneumonia (CAP).
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Community Acquired Pneumonia (CAP) market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Community Acquired Pneumonia (CAP) market by product type and applications/end industries.
Market Segment by Companies, this report covers
Pfizer
Astrazeneca
Bioaegis Therapeutics
Biotest
C10 Pharma
Kyorin Pharmaceutical
Melinta Therapeutics
Merck
Nabriva Therapeutics
Paratek Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Chest X-ray/Radiography
Sputum Gram Stain and/or Culture
Blood Cultures
Market Segment by Applications, can be divided into
Hospitals and Clinics
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Community Acquired Pneumonia (CAP) Market Overview
1.1 Product Overview and Scope of Community Acquired Pneumonia (CAP)
1.2 Classification of Community Acquired Pneumonia (CAP) by Types
1.2.1 Global Community Acquired Pneumonia (CAP) Revenue Comparison by Types (2017-2023)
1.2.2 Global Community Acquired Pneumonia (CAP) Revenue Market Share by Types in 2017
1.2.3 Chest X-ray/Radiography
1.2.4 Sputum Gram Stain and/or Culture
1.2.5 Blood Cultures
1.3 Global Community Acquired Pneumonia (CAP) Market by Application
1.3.1 Global Community Acquired Pneumonia (CAP) Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals and Clinics
1.3.3 Others
1.4 Global Community Acquired Pneumonia (CAP) Market by Regions
1.4.1 Global Community Acquired Pneumonia (CAP) Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Community Acquired Pneumonia (CAP) Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Community Acquired Pneumonia (CAP) Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Community Acquired Pneumonia (CAP) Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Community Acquired Pneumonia (CAP) Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Community Acquired Pneumonia (CAP) Status and Prospect (2013-2023)
1.5 Global Market Size of Community Acquired Pneumonia (CAP) (2013-2023)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Business Overview
2.1.2 Community Acquired Pneumonia (CAP) Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Pfizer Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2016-2017)
2.2 Astrazeneca
2.2.1 Business Overview
2.2.2 Community Acquired Pneumonia (CAP) Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Astrazeneca Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2016-2017)
2.3 Bioaegis Therapeutics
2.3.1 Business Overview
2.3.2 Community Acquired Pneumonia (CAP) Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Bioaegis Therapeutics Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2016-2017)
2.4 Biotest
2.4.1 Business Overview
2.4.2 Community Acquired Pneumonia (CAP) Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Biotest Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2016-2017)
2.5 C10 Pharma
2.5.1 Business Overview
2.5.2 Community Acquired Pneumonia (CAP) Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 C10 Pharma Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2016-2017)
2.6 Kyorin Pharmaceutical
2.6.1 Business Overview
2.6.2 Community Acquired Pneumonia (CAP) Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Kyorin Pharmaceutical Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2016-2017)
2.7 Melinta Therapeutics
2.7.1 Business Overview
2.7.2 Community Acquired Pneumonia (CAP) Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Melinta Therapeutics Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2016-2017)
2.8 Merck
2.8.1 Business Overview
2.8.2 Community Acquired Pneumonia (CAP) Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Merck Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2016-2017)
2.9 Nabriva Therapeutics
2.9.1 Business Overview
2.9.2 Community Acquired Pneumonia (CAP) Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Nabriva Therapeutics Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2016-2017)
2.10 Paratek Pharmaceuticals
2.10.1 Business Overview
2.10.2 Community Acquired Pneumonia (CAP) Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Paratek Pharmaceuticals Community Acquired Pneumonia (CAP) Revenue, Gross Margin and Market Share (2016-2017)
3 Global Community Acquired Pneumonia (CAP) Market Competition, by Players
3.1 Global Community Acquired Pneumonia (CAP) Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Community Acquired Pneumonia (CAP) Players Market Share
3.2.2 Top 10 Community Acquired Pneumonia (CAP) Players Market Share
3.3 Market Competition Trend
4 Global Community Acquired Pneumonia (CAP) Market Size by Regions
4.1 Global Community Acquired Pneumonia (CAP) Revenue and Market Share by Regions
4.2 North America Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
4.3 Europe Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
4.5 South America Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
5 North America Community Acquired Pneumonia (CAP) Revenue by Countries
5.1 North America Community Acquired Pneumonia (CAP) Revenue by Countries (2013-2018)
5.2 USA Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
5.3 Canada Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
5.4 Mexico Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
6 Europe Community Acquired Pneumonia (CAP) Revenue by Countries
6.1 Europe Community Acquired Pneumonia (CAP) Revenue by Countries (2013-2018)
6.2 Germany Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
6.3 UK Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
6.4 France Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
6.5 Russia Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
6.6 Italy Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Community Acquired Pneumonia (CAP) Revenue by Countries
7.1 Asia-Pacific Community Acquired Pneumonia (CAP) Revenue by Countries (2013-2018)
7.2 China Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
7.3 Japan Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
7.4 Korea Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
7.5 India Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
8 South America Community Acquired Pneumonia (CAP) Revenue by Countries
8.1 South America Community Acquired Pneumonia (CAP) Revenue by Countries (2013-2018)
8.2 Brazil Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
8.3 Argentina Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
8.4 Colombia Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Community Acquired Pneumonia (CAP) by Countries
9.1 Middle East and Africa Community Acquired Pneumonia (CAP) Revenue by Countries (2013-2018)
9.2 Saudi Arabia Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
9.3 UAE Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
9.4 Egypt Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
9.5 Nigeria Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
9.6 South Africa Community Acquired Pneumonia (CAP) Revenue and Growth Rate (2013-2018)
10 Global Community Acquired Pneumonia (CAP) Market Segment by Type
10.1 Global Community Acquired Pneumonia (CAP) Revenue and Market Share by Type (2013-2018)
10.2 Global Community Acquired Pneumonia (CAP) Market Forecast by Type (2018-2023)
10.3 Chest X-ray/Radiography Revenue Growth Rate (2013-2023)
10.4 Sputum Gram Stain and/or Culture Revenue Growth Rate (2013-2023)
10.5 Blood Cultures Revenue Growth Rate (2013-2023)
11 Global Community Acquired Pneumonia (CAP) Market Segment by Application
11.1 Global Community Acquired Pneumonia (CAP) Revenue Market Share by Application (2013-2018)
11.2 Community Acquired Pneumonia (CAP) Market Forecast by Application (2018-2023)
11.3 Hospitals and Clinics Revenue Growth (2013-2018)
11.4 Others Revenue Growth (2013-2018)
12 Global Community Acquired Pneumonia (CAP) Market Size Forecast (2018-2023)
12.1 Global Community Acquired Pneumonia (CAP) Market Size Forecast (2018-2023)
12.2 Global Community Acquired Pneumonia (CAP) Market Forecast by Regions (2018-2023)
12.3 North America Community Acquired Pneumonia (CAP) Revenue Market Forecast (2018-2023)
12.4 Europe Community Acquired Pneumonia (CAP) Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Community Acquired Pneumonia (CAP) Revenue Market Forecast (2018-2023)
12.6 South America Community Acquired Pneumonia (CAP) Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Community Acquired Pneumonia (CAP) Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Community Acquired Pneumonia (CAP) Picture
Table Product Specifications of Community Acquired Pneumonia (CAP)
Table Global Community Acquired Pneumonia (CAP) and Rev
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
